|
|
| | JAK-IN-30 Basic information |
| Product Name: | JAK-IN-30 | | Synonyms: | JAK-IN-30;JAK Inhibitor 31;3-Azetidineacetonitrile, 1-[5-methyl-2-[(3-methyl-5-isothiazolyl)amino]-4-pyrimidinyl]-3-(4-methyl-1-piperazinyl)- | | CAS: | 2891469-99-9 | | MF: | C19H26N8S | | MW: | 398.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2891469-99-9.mol |  |
| | JAK-IN-30 Chemical Properties |
| Boiling point | 565.197±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.304±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | DMF: 30 mg/ml
DMSO: 30 mg/ml
Ethanol: 10 mg/mlPBS (pH 7.2): Slightly soluble | | pka | 8.074±0.42(predicted) |
| | JAK-IN-30 Usage And Synthesis |
| Uses | JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED)[1]. | | IC 50 | JAK1: 15 nM (IC50); JAK2: 2 nM (IC50); JAK3: 18 nM (IC50); Tyk2: 2 nM (IC50) | | References | [1] Gordhan HM, et al. Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. J Med Chem. 2023 Jul 13;66(13):8929-8950. DOI:10.1021/acs.jmedchem.3c00519 |
| | JAK-IN-30 Preparation Products And Raw materials |
|